{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:16:23Z","timestamp":1779340583094,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD Spain, Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Achieving and maintaining a low-risk profile is associated with favorable outcome in pulmonary arterial hypertension (PAH). The effects of treatment on risk profile are variable among patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To Identify variables that might predict the response to treatment with phosphodiesterase-5 inhibitors (PDE-5i) in PAH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We carried out a cohort analysis of the Spanish PAH registry in 830 patients diagnosed with PAH that started PDE5i treatment and had\u2009&gt;\u20091\u00a0year follow-up. 644 patients started PDE-5i either in mono- or add-on therapy and 186 started combined treatment with PDE-5i and endothelin receptor antagonist (ERA). Responders were considered when at 1 year\u00a0they: (1) were alive; (2) did not present clinical worsening; and (3) improved European Society of Cardiology\/European Respiratory Society (ESC\/ERS) risk score or remained in low-risk. Univariate and multivariate logistic regression models were used to analyze variables associated with a favorable response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two hundred and ten patients (33%) starting PDE-5i alone were classified as responders, irrespective of whether it was mono- or add-on therapy. In addition to known predictors of PAH outcome (low-risk at baseline, younger age), male sex and diagnosis of portopulmonary hypertension (PoPH) or HIV-PAH were independent predictors of favorable response to PDE-5i. Diffusing capacity for carbon monoxide (DLco)\u2009\u2264\u200940% of predicted was associated with an unfavorable response. When PDE-5i were used in upfront combination, 58% of patients were responders. In this group, diagnosis of idiopathic PAH (IPAH) was an independent predictor of favorable response, whereas connective tissue disease-PAH was associated with an unfavorable response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Male sex and diagnosis of PoPH or HIV-PAH are predictors of favorable effect of PDE-5i on risk profile when used as mono- or add-on therapy. Patients with IPAH respond more favorably to PDE-5i when used in upfront combination. These results identify patient profiles that may respond favorably to PDE-5i in monotherapy and those who might benefit from alternative treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02531-1","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T07:14:37Z","timestamp":1694762077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry"],"prefix":"10.1186","volume":"24","author":[{"given":"Agustin R.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"P\u00e9rez-Sagredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Guerra-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Mart\u00edn-Ontiyuelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Tura-Ceide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Pastor-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Escribano-Sub\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan A.","family":"Barber\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"3","key":"2531_CR1","first-page":"286","volume":"74","author":"Y Tamura","year":"2015","unstructured":"Tamura Y, Kimura M. Treatment of pulmonary arterial hypertension. Japanese J Chest Dis. 2015;74(3):286\u201394.","journal-title":"Japanese J Chest Dis"},{"key":"2531_CR2","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Channick RN, Frantz RP, Gr\u00fcnig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019.","DOI":"10.1183\/13993003.01889-2018"},{"key":"2531_CR3","doi-asserted-by":"crossref","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022.","DOI":"10.1183\/13993003.00879-2022"},{"key":"2531_CR4","doi-asserted-by":"crossref","unstructured":"Boucly A, Weatherald J, Savale L, Ja\u00efs X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2).","DOI":"10.1183\/13993003.00889-2017"},{"issue":"47","key":"2531_CR5","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","volume":"39","author":"D Kylhammar","year":"2018","unstructured":"Kylhammar D, Kjellstr\u00f6m B, Hjalmarsson C, Jansson K, Nisell M, S\u00f6derberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175\u201381.","journal-title":"Eur Heart J"},{"key":"2531_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijcard.2020.05.044","volume":"317","author":"RL Benza","year":"2020","unstructured":"Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, et al. Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. Int J Cardiol. 2020;317:188\u201392.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2531_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-020-01197-5","volume":"20","author":"P Escribano-Subias","year":"2020","unstructured":"Escribano-Subias P, L\u00f3pez R, Almenar L, L\u00e1zaro M, Forn I, Torrent A, et al. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. BMC Pulm Med. 2020;20(1):1\u201310.","journal-title":"BMC Pulm Med"},{"key":"2531_CR8","doi-asserted-by":"crossref","unstructured":"Badagliacca R, Papa S, Rischard F. Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. J Heart Lung Transplant; 2021. p. 166\u20137.","DOI":"10.1016\/j.healun.2020.11.001"},{"issue":"12","key":"2531_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","volume":"39","author":"MM Hoeper","year":"2020","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Klose H, Staehler G, Huscher D, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020;39(12):1435\u201344.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"2531_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","volume":"172","author":"J Wharton","year":"2005","unstructured":"Wharton J, Strange JW, M\u00f8ller GMO, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2531_CR11","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karada\u015f B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2531_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","volume":"9","author":"MM Hoeper","year":"2021","unstructured":"Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(6):573\u201384.","journal-title":"Lancet Respir Med"},{"key":"2531_CR13","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Gr\u00fcnig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1).","DOI":"10.1183\/13993003.02311-2021"},{"issue":"4","key":"2531_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","volume":"39","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transplant. 2020;39(4):300\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"2531_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1378\/chest.11-1460","volume":"142","author":"RL Benza","year":"2012","unstructured":"Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012;142(2):448\u201356.","journal-title":"Chest"},{"issue":"1","key":"2531_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jhep.2020.02.021","volume":"73","author":"L Savale","year":"2020","unstructured":"Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020;73(1):130\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"2531_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1183\/09031936.06.00030206","volume":"28","author":"F Reichenberger","year":"2006","unstructured":"Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28(3):563\u20137.","journal-title":"Eur Respir J"},{"issue":"11","key":"2531_CR18","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1097\/00002030-200207260-00021","volume":"16","author":"J Carlsen","year":"2002","unstructured":"Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS. 2002;16(11):1568\u20139.","journal-title":"AIDS"},{"issue":"Suppl 2","key":"2531_CR19","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.2459\/JCM.0b013e3283388fb3","volume":"16","author":"V Pergola","year":"2015","unstructured":"Pergola V, Caruso C, Gnarini R, Fazio S, Ferraro S. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension. J Cardiovasc Med (Hagerstown). 2015;16(Suppl 2):S136\u20137.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"13","key":"2531_CR20","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1097\/00002030-200109070-00026","volume":"15","author":"YO Schumacher","year":"2001","unstructured":"Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001;15(13):1747\u20138.","journal-title":"AIDS"},{"issue":"3","key":"2531_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/imj.14751","volume":"51","author":"M Lazaro Salvador","year":"2021","unstructured":"Lazaro Salvador M, Quezada Loaiza CA, Rodr\u00edguez Padial L, Barber\u00e1 JA, L\u00f3pez-Meseguer M, L\u00f3pez-Reyes R, et al. Portopulmonary hypertension: prognosis and management in the current treatment era\u2014results from the REHAP registry. Intern Med J. 2021;51(3):355\u201365.","journal-title":"Intern Med J"},{"issue":"1","key":"2531_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13468","volume":"292","author":"ML Salvador","year":"2022","unstructured":"Salvador ML, Rodr\u00edguez-Padial L, Soto Ab\u00e1nades C, Cruz Utrilla A, Barber\u00e1 Mir JA, L\u00f3pez-Meseguer M, et al. Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. J Intern Med. 2022;292(1):116\u201326.","journal-title":"J Intern Med"},{"issue":"7","key":"2531_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","volume":"7","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594\u2013604.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2531_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/lt.21533","volume":"15","author":"MS Gough","year":"2009","unstructured":"Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl. 2009;15(1):30\u20136.","journal-title":"Liver Transpl"},{"issue":"4","key":"2531_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/A:1021957818240","volume":"17","author":"J Gonz\u00e1lez-Abraldes","year":"2002","unstructured":"Gonz\u00e1lez-Abraldes J, Garc\u00eda-Pag\u00e1n JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis. 2002;17(4):311\u201324.","journal-title":"Metab Brain Dis"},{"issue":"1","key":"2531_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0168-8278(97)80012-8","volume":"26","author":"S Battista","year":"1997","unstructured":"Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol. 1997;26(1):75\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"2531_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7326\/0003-4819-99-1-9","volume":"99","author":"RG Pearl","year":"1983","unstructured":"Pearl RG, Rosenthal MH, Schroeder JS, Ashton JP. Acute hemodynamic effects of nitroglycerin in pulmonary hypertension. Ann Intern Med. 1983;99(1):9\u201313.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2531_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1034\/j.1399-3003.1999.13a38.x","volume":"13","author":"J Ribas","year":"1999","unstructured":"Ribas J, Angrill J, Barber\u00e0 JA, Garc\u00eda-Pag\u00e1n JC, Roca J, Bosch J, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J. 1999;13(1):210\u20132.","journal-title":"Eur Respir J"},{"issue":"7","key":"2531_CR29","volume":"14","author":"JJ Palakeel","year":"2022","unstructured":"Palakeel JJ, Ali M, Chaduvula P, Chhabra S, LamsalLamichhane S, Ramesh V, et al. An outlook on the etiopathogenesis of pulmonary hypertension in HIV. Cureus. 2022;14(7): e27390.","journal-title":"Cureus"},{"issue":"6","key":"2531_CR30","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.chest.2022.06.042","volume":"162","author":"S Wu","year":"2022","unstructured":"Wu S, Hoang HB, Yang JZ, Papamatheakis DG, Poch DS, Alotaibi M, et al. Drug\u2013drug interactions in the management of patients with pulmonary arterial hypertension. Chest. 2022;162(6):1360\u201372.","journal-title":"Chest"},{"key":"2531_CR31","doi-asserted-by":"crossref","unstructured":"Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999;13(15).","DOI":"10.1097\/00002030-199910220-00001"},{"issue":"2","key":"2531_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1365-2125.2000.00245.x","volume":"50","author":"GJ Muirhead","year":"2000","unstructured":"Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir\/ritonavir. Br J Clin Pharmacol. 2000;50(2):99\u2013107.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2531_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1183\/09031936.00101211","volume":"40","author":"P Escribano-Subias","year":"2012","unstructured":"Escribano-Subias P, Blanco I, L\u00f3pez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596\u2013603.","journal-title":"Eur Respir J"},{"issue":"2","key":"2531_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1378\/chest.10-3114","volume":"141","author":"S Shapiro","year":"2012","unstructured":"Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012;141(2):363\u201373.","journal-title":"Chest"},{"key":"2531_CR35","doi-asserted-by":"crossref","unstructured":"McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al., editors. Pulmonary arterial hypertension: epidemiology and registries. 2013; J Am Coll Cardiol.","DOI":"10.1016\/j.jacc.2013.10.023"},{"issue":"1","key":"2531_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1378\/chest.14-0263","volume":"147","author":"SC Mathai","year":"2015","unstructured":"Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest. 2015;147(1):188\u201397.","journal-title":"Chest"},{"issue":"6","key":"2531_CR37","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1172\/JCI70731","volume":"124","author":"H Sasaki","year":"2014","unstructured":"Sasaki H, Nagayama T, Blanton RM, Seo K, Zhang M, Zhu G, et al. PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Investig. 2014;124(6):2464\u201371.","journal-title":"J Clin Investig"},{"issue":"4","key":"2531_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/01.HYP.32.4.730","volume":"32","author":"P Forte","year":"1998","unstructured":"Forte P, Kneale BJ, Milne E, Chowienczyk PJ, Johnston A, Benjamin N, et al. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension. 1998;32(4):730\u20134.","journal-title":"Hypertension"},{"issue":"1","key":"2531_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1378\/chest.11-0404","volume":"141","author":"NB Gabler","year":"2012","unstructured":"Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012;141(1):20\u20136.","journal-title":"Chest"},{"issue":"4","key":"2531_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1476-5381.2012.02012.x","volume":"167","author":"MV Chan","year":"2012","unstructured":"Chan MV, Bubb KJ, Noyce A, Villar IC, Duchene J, Hobbs AJ, et al. Distinct endothelial pathways underlie sexual dimorphism in vascular auto-regulation. Br J Pharmacol. 2012;167(4):805\u201317.","journal-title":"Br J Pharmacol"},{"key":"2531_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2019.10.043","volume":"301","author":"R Badagliacca","year":"2020","unstructured":"Badagliacca R, Papa S, Matsubara H, Lang IM, Poscia R, Manzi G, et al. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: raising the bar in pulmonary arterial hypertension. Int J Cardiol. 2020;301:183\u20139.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2531_CR42","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"2531_CR43","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.healun.2018.07.001","volume":"37","author":"AE Frost","year":"2018","unstructured":"Frost AE, Hoeper MM, Barber\u00e1 JA, Vachiery JL, Blair C, Langley J, et al. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: application of the REVEAL risk score. J Heart Lung Transplant. 2018;37(12):1410\u20137.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"2531_CR44","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","volume":"203","author":"R Badagliacca","year":"2021","unstructured":"Badagliacca R, D\u2019Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;203(4):484\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2531_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","volume":"204","author":"A Boucly","year":"2021","unstructured":"Boucly A, Savale L, Ja\u00efs X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204(7):842\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2531_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1536\/ihj.21-497","volume":"63","author":"M Hatano","year":"2022","unstructured":"Hatano M, Abe K, Koike G, Takahashi T, Tunmer G, Kiely DG. Positive predictors for response to ambrisentan combination therapy in pulmonary arterial hypertension. Int Heart J. 2022;63(1):99\u2013105.","journal-title":"Int Heart J"},{"issue":"6","key":"2531_CR47","doi-asserted-by":"publisher","first-page":"2102024","DOI":"10.1183\/13993003.02024-2021","volume":"59","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59(6):2102024.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02531-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:19:01Z","timestamp":1700381941000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02531-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02531-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.R.G. reports consulting fees from Janssen; speaker fees from MSD, Ferrer and Janssen and travel support from Janssen, Menarini, Tuteur and MSD. I.B.V. reports consulting and speaker fees from Janssen, MSD, and Ferrer and travel support from Janssen and MSD. F.P.P. received consulting and speaker fees from Janssen, AOP and MSD. F.J.G.R. reports speaker fees from Janssen, MSD and Ferrer. P.E.S reports consulting fees from Janssen, MSD, Ferrer, GOSSAMER and AOP; speaker fees from Janssen, MSD, Ferrer and AOP; travel support from Janssen and MSD. J.A.B reports consulting fees from MSD, Janssen and Acceleron Pharma; speaker fees from Ferrer, Janssen and MSD; travel support from MSD and Janssen. L.R., J.P.S, C.M.O. and O.T.C. have not reported any potential competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}